These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17665889)

  • 1. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
    Moriconi A; Cesta MC; Cervellera MN; Aramini A; Coniglio S; Colagioia S; Beccari AR; Bizzarri C; Cavicchia MR; Locati M; Galliera E; Di Benedetto P; Vigilante P; Bertini R; Allegretti M
    J Med Chem; 2007 Aug; 50(17):3984-4002. PubMed ID: 17665889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
    Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.
    Garau A; Bertini R; Mosca M; Bizzarri C; Anacardio R; Triulzi S; Allegretti M; Ghezzi P; Villa P
    Eur Cytokine Netw; 2006 Mar; 17(1):35-41. PubMed ID: 16613761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
    Allegretti M; Bertini R; Cesta MC; Bizzarri C; Di Bitondo R; Di Cioccio V; Galliera E; Berdini V; Topai A; Zampella G; Russo V; Di Bello N; Nano G; Nicolini L; Locati M; Fantucci P; Florio S; Colotta F
    J Med Chem; 2005 Jun; 48(13):4312-31. PubMed ID: 15974585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.
    Biju P; Taveras A; Yu Y; Zheng J; Chao J; Rindgen D; Jakway J; Hipkin RW; Fossetta J; Fan X; Fine J; Qiu H; Merritt JR; Baldwin JJ
    Bioorg Med Chem Lett; 2008 Jan; 18(1):228-31. PubMed ID: 18006311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DF2755A, a novel non-competitive allosteric inhibitor of CXCR1/2, reduces inflammatory and post-operative pain.
    Lopes AH; Brandolini L; Aramini A; Bianchini G; Silva RL; Zaperlon AC; Verri WA; Alves-Filho JC; Cunha FQ; Teixeira MM; Allegretti M; Cunha TM
    Pharmacol Res; 2016 Jan; 103():69-79. PubMed ID: 26592483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors.
    Sablone MR; Cesta MC; Moriconi A; Aramini A; Bizzarri C; Di Giacinto C; Di Bitondo R; Gloaguen I; Aschi M; Crucianelli M; Bertini R; Allegretti M
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4026-30. PubMed ID: 19560921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
    Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
    Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6.
    Catusse J; Struyf S; Wuyts A; Weyler M; Loos T; Gijsbers K; Gouwy M; Proost P; Van Damme J
    Biochem Pharmacol; 2004 Nov; 68(10):1947-55. PubMed ID: 15476666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.
    Bizzarri C; Beccari AR; Bertini R; Cavicchia MR; Giorgini S; Allegretti M
    Pharmacol Ther; 2006 Oct; 112(1):139-49. PubMed ID: 16720046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.
    Maeda DY; Peck AM; Schuler AD; Quinn MT; Kirpotina LN; Wicomb WN; Fan GH; Zebala JA
    J Med Chem; 2014 Oct; 57(20):8378-97. PubMed ID: 25254640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.
    Chao J; Taveras AG; Chao J; Aki C; Dwyer M; Yu Y; Purakkattle B; Rindgen D; Jakway J; Hipkin W; Fosetta J; Fan X; Lundell D; Fine J; Minnicozzi M; Phillips J; Merritt JR
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3778-83. PubMed ID: 17459706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2.
    Nicholls DJ; Tomkinson NP; Wiley KE; Brammall A; Bowers L; Grahames C; Gaw A; Meghani P; Shelton P; Wright TJ; Mallinder PR
    Mol Pharmacol; 2008 Nov; 74(5):1193-202. PubMed ID: 18676678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.
    Yu Y; Dwyer MP; Chao J; Aki C; Chao J; Purakkattle B; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Qiu H; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; He Z; Lai G; Wu M; Taveras A
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1318-22. PubMed ID: 18242983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with DF 2162, a non-competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in mice.
    Cunha TM; Barsante MM; Guerrero AT; Verri WA; Ferreira SH; Coelho FM; Bertini R; Di Giacinto C; Allegretti M; Cunha FQ; Teixeira MM
    Br J Pharmacol; 2008 May; 154(2):460-70. PubMed ID: 18362895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats.
    Barsante MM; Cunha TM; Allegretti M; Cattani F; Policani F; Bizzarri C; Tafuri WL; Poole S; Cunha FQ; Bertini R; Teixeira MM
    Br J Pharmacol; 2008 Mar; 153(5):992-1002. PubMed ID: 17891165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.
    Widdowson KL; Elliott JD; Veber DF; Nie H; Rutledge MC; McCleland BW; Xiang JN; Jurewicz AJ; Hertzberg RP; Foley JJ; Griswold DE; Martin L; Lee JM; White JR; Sarau HM
    J Med Chem; 2004 Mar; 47(6):1319-21. PubMed ID: 14998320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor.
    Bertini R; Barcelos LS; Beccari AR; Cavalieri B; Moriconi A; Bizzarri C; Di Benedetto P; Di Giacinto C; Gloaguen I; Galliera E; Corsi MM; Russo RC; Andrade SP; Cesta MC; Nano G; Aramini A; Cutrin JC; Locati M; Allegretti M; Teixeira MM
    Br J Pharmacol; 2012 Jan; 165(2):436-54. PubMed ID: 21718305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases.
    Russo RC; Garcia CC; Teixeira MM; Amaral FA
    Expert Rev Clin Immunol; 2014 May; 10(5):593-619. PubMed ID: 24678812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.
    Kaur M; Singh D
    J Pharmacol Exp Ther; 2013 Oct; 347(1):173-80. PubMed ID: 23912333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.